Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1013919 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Trevor Cross und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Cornell University, Ithaca, New York, United States of America. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, Klebsiella Infections, Drug Resistance, Bacterial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Antibiotic tolerance is the ability of bacteria to survive normally lethal doses of antibiotics for extended time periods. Clinically significant Enterobacterales, for example, can exhibit high tolerance to the last-resort antibiotic meropenem. Meropenem tolerance is associated with formation of cell wall-deficient spheroplasts that readily recover to rod shape and normal growth upon removal of the antibiotic. Both the true prevalence of tolerance, and genetic mechanisms underlying it, remain poorly understood. Here, we find that meropenem tolerance is widespread among clinical Enterobacterales. Using forward genetics, we uncover tolerance factors in a hypertolerant isolate of the ESKAPE pathogen Klebsiella pneumoniae . We find that multiple mechanisms contribute to tolerance, and that cell envelope stress responses (PhoPQ, CpxPRA, Rcs phosphorelay and OmpR/EnvZ) collectively promote spheroplast stability and recovery, while the lytic transglycosylase MltB counteracts it. Our data indicate that tolerance is widespread among clinical isolates, and that outer membrane maintenance is a key factor promoting survival of tolerant K. pneumoniae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Cornell University, Ithaca, New York, United States of America.
- Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, United States of America.
- Departments of Pathology and Laboratory Medicine, Medicine, and Pediatrics, Weill Cornell Medicine, New York, New York, United States of America.
- Department of Electrical and Computer Engineering, University of Delaware, Newark, Delaware, United States of America.
- Cornell Institute for Host-Microbe Interactions and Disease (CIHMID), Cornell University, Ithaca, New York, United States of America.
- Cornell Center for Antimicrobial Resistance Research and Education (CCARRE), Cornell University, Ithaca, New York, United States of America.
ORCID-Profile: Tobias Dörr
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Cross, T., Torres, F., Nikulin, N., McGee, A. P., Jalees, L., Balakrishnan, R., Aliyu, T., Westblade, L. F., Singh, A., & Dörr, T. (2026). Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013919
Vancouver
Cross T, Torres F, Nikulin N, McGee AP, Jalees L, Balakrishnan R, et al. Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013919
BibTeX
@article{Cross2026,
author = {Cross, Trevor and Torres, Facundo and Nikulin, Nadia and McGee, Abigail P and Jalees, Leena and Balakrishnan, Rhea and Aliyu, Tolani and Westblade, Lars F and Singh, Abhyudai and Dörr, Tobias},
title = {Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1013919}
}
EUVIMED